In Vitro: Fasnall potently blocks both acetate and glucose incorporation into total lipids, with IC50 values of 147 and 213 nM, respectively, in HepG2 cells. Fasnall (50 μM; 24-120 h) inhibits proliferation in breast cancer cell lines. Fasnall (25-100 μM; 24 h) induces apoptosis in HER2+ breast cancer cell lines.
In Vivo: Fasnall (15 mg/kg, intraperitoneally, twice weekly; 3 weeks) shows potent anti-tumor activity in MMTV-Neu model of HER2+ breast cancer.